What caused Roche's Huntington's drug tominersen to hit the skids in late-stage test? It's complicated, analysts say
Just last month, Roche hit the pause button on a Phase III test for Huntington’s hopeful tominersen after a data committee questioned its risk/benefit profile. Now, the drugmaker is conducting an autopsy to see what went wrong, but answers are in short supply.
On Tuesday, Roche presented follow-up data from tominersen that sought to provide some clue behind why the drugmaker halted its Phase III test. The answer? It’s complicated, Stifel analysts wrote in a note to clients Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.